Hawkey CJ.
The Lancet. 1999;353:307-314

Celecoxib and rofecoxib, two cyclooxygenase-2 inhibitors, are likely to have a positive impact on the treatment of inflammation and pain associated with osteoarthritis and rheumatoid arthritis, and break the prostaglandin-dependent link between efficacy and GI toxicity. Conventional NSAIDs, in spite of their GI side effects, are one of the most commonly prescribed drugs. However, before COX-2 SIs can be seen as a "therapeutic revolution" some questions need to be answered:

• Are COX-2 inhibitors safe in those with GI inflammation?
  
• Will COX-2 inhibitors slow ulcer healing?
  
• Are COX-2 inhibitors safe in those patients who are more likely to develop ulcers or those with a previous history of ulcers?
  
• Will COX-2 inhibitors cause fluid retention, renal failure or exacerbate hypertension?
  
• What is the effect of COX-2 inhibitors on the incidence of vascular disease?
  

Content on this site has been reviewed by the arthritisU.com faculty. A listing of the faculty is located in the Faculty Lounge.